| 53 | 0 | 20 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 探讨他汀类药物对高龄卧床住院患者住院期间发生静脉血栓栓塞(venous thromboembolism, VTE)的预防价值。方法 采用回顾性分析方法,随机调取2023年1月至2025年1月我院内科收治的280例高龄卧床住院患者临床资料,分析药物使用情况。选取入院前规律服用他汀类药物14天的患者为他汀组(n=128),入院前14 d未服用他汀类药物的患者为非他汀组(n=152)。观察分析两组发生肺血栓栓塞、深静脉血栓栓塞情况及性别、年龄、基础疾病、治疗方案、血脂、炎性标志物、凝血标志物等各项指标情况。结果 他汀组患者VTE发生率4.68%(6/128)显著低于非他汀组的9.21%(14/152)(P<0.05),其中他汀组下肢深静脉血栓发生率2.34%(3/128)显著低于非他汀组7.23%(11/152)(P<0.05)。与非他汀组相比,他汀组患者白细胞计数(white blood cell count, WBC)、血清C反应蛋白(C-reactive protein, CRP)水平、D二聚体(D-Dimer, D-D)水平、总胆固醇(total cholesterol, TC)水平、低密度脂蛋白胆固醇(low-density lipoprotein cholesterol, LDL-C)水平均显著降低(P<0.05)。Logistic多因素回归分析提示血清D-D、CRP、LDL水平是VTE发生的独立影响因素,差异有统计学意义(P<0.05)。结论 他汀类药物能降低高龄卧床住院患者血清CRP、D-D、LDL-C水平,降低高龄卧床患者VTE的发生风险,对预防高龄卧床住院患者发生VTE具有一定的保护作用。
Abstract:Objective To investigate the preventive value of statins on venous thromboembolism(VTE) in elderly bedridden patients during hospitalization. Methods The clinical data of 280 elderly bedridden patients admitted to the internal medicine department of Guizhou People's Hospital from January 2023 to January 2025 were randomly selected by retrospective analysis to analyze the use of drugs.Patients who regularly took statins for 14 days before admission were selected as the statin group(n=128), and those who did not taken statins for 14 days before admission were selected as the non-statin group(n=152). Pulmonary thromboembolism, deep venous thromboembolism, gender, age, underlying diseases, treatment plan, blood lipid, inflammatory markers, coagulation markers and other indicators of the two groups were observed and analyzed. Results The incidence of VTE in the statin group was 4.68%(6/128) significantly lower than that in the non-statin group 9.21%(14/152), there were statistically significantdifferences(P<0.05),and the incidence of lower extremity deep vein thrombosis in the statin group was significantly lower than that in the non-statin group, and there were statistically significantdifferences(P<0.05).Compared with non-statin group, serum CRP,D-D,TC and LDL-C in statin group were significantly decreased, there were statistically significantdifferences(P<0.05).Logistic multivariate regression analysis indicated that serum D-D,CRP and LDL levels were independent factors affecting the occurrence of VTE, and also there were statistically significantdifferences(P<0.05). Conclusion Statins can reduce the serum levels of CRP,D-D and LDL-C in elderly bedridden patients, reduce the risk of VTE in elderly bedridden patients, and have a certain protective effect on preventing VTE in elderly bedridden patients.
[1] Mismetti P,Bertoletti L,Gouin I,et al.Elderly patients with venous thromboembolism:Insights from the RIETE registry[J].Presse Med,2024,53(4):104246.
[2] 王海军,元钰鑫,司全金,等.高龄卧床高危静脉血栓栓塞症防治中国专家共识[J].中华老年心脑血管病杂志,2024,26(12):1381-1389.
[3] 吴洲鹏,李凤贺,戴贻权,等.老年人静脉血栓栓塞症防治中国专家共识[J].中国普外基础与临床杂志,2023,30(10):1173-1187.
[4] Ma XS,Sun J,Geng R,et al.Statins and risk of venous thromboembolic diseases:a two-sample mendelian randomization study[J].Nutr Metab Cardiovasc Dis,2023,33(5):1087-1092.
[5] 朱扬媚,曹建刚,周玉生.基因检测在降脂药物个体化治疗中的应用[J].中国药房,2023,34(9):1147-1152.
[6] Hsu C,Brahmandam A,Brownson KE,et al.Statin therapy associated with improved thrombus resolution in patients with deep vein thrombosis[J].J Vasc Surg Venous Lymphat Disord,2019,7(2):169-175.
[7] Delluc A,Ghanima W,Kovacs MJ,et al.Statins for venous event reduction in patients with venous thromboembolism:A multicenter randomized controlled pilot trial assessing feasibility[J].J Thromb Haemost,2022,20(1):126-132.
[8] Hansen ES,Rinde FB,Edvardsen MS,et al.Elevated plasma D-dimer levels are associated with risk of future incident venous thromboembolism[J].Thromb Res,2021,208:121-126.
[9] Farmakis IT,Christodoulou KC,Hobohm L,et al.Lipid lowering for prevention of venous thromboembolism:a network meta-analysis[J].Eur Heart J,2024,45(35):3219-3227.
[10] Liao JK.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J].Curr Atheroscler Rep,2009,11(4):243-244.
[11] Mora S,Ridker PM.Justification for the Use of statins in primary prevention:an intervention trial evaluating rosuvastatin(JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention?[J].Am J Cardiol,2006,97(2A):33A-41A.
[12] St?pień K,Siudut J,Konieczyńska M,et al.Effect of high-dose statin therapy on coagulation factors:Lowering of factor Ⅺ as a modifier of fibrin clot properties in coronary artery disease[J].Vascul Pharmacol,2023,149:107153.
[13] Kunutsor SK,Seidu S,Khunti K.Statins and primary prevention of venous thromboembolism:a systematic review and meta-analysis[J].Lancet Haematol,2017,4(2):e83-e93.
[14] 刘艳红,王京伟,武军驻.TLR4-TLR10-CD36的识别和炎症信号转导可能参与细胞内天然低密度脂蛋白氧化[J].中国动脉硬化杂志,2019,(11):921-929.
[15] Poredo? P,Mukherjee D,Blinc A.Statins and venous thromboembolic disease-where are we now?[J].Curr Vasc Pharmacol,2024,22(4):297-300.
[16] Zaccardi F,Kunutsor SK,Seidu S,et al.Is the lower risk of venous thromboembolism with statins related to low-density-lipoprotein reduction?A network meta-analysis and meta-regression of randomised controlled trials[J].Atherosclerosis,2018,271:223-231.
基本信息:
DOI:
中图分类号:R969
引用信息:
[1]胡琼,曾雪琴,余倩,等.他汀类药物对高龄卧床住院患者血清CRP、D-D、LDL-C的影响及对静脉血栓栓塞症的预防作用[J].贵州医药,2025,49(10):1518-1522.
基金信息:
贵州省卫生健康委科学技术基金项目(GZWKZ2021-094);贵州省卫生健康委科学技术基金项目(gzwkj2021-089);贵州省卫生健康委科学技术基金项目(gzwkj2021-091)、[黔科合基础-ZK(2022)一般248]、[黔科合基础-ZK(2024)一般477]; 贵州省人民医院青年基金[GZSYQN(2021)15号]; 贵州省高层次创新型人才“千层次”人才培养项目资助支持[GZSYQCC(2023)007]